Aranda, C., Gouveia-Pereira, M., França, M., Curiati, M., Sole, D., Kishnani, P., & Martins, A. M. (2020). Infantile-onset Pompe disease and CRIM negative status: Immunomodulation with intravenous immunoglobulin as an alternative for regular immune tolerance induction. In Molecular Genetics and Metabolism (Vol. 129, pp. S22–S22). Elsevier BV. https://doi.org/10.1016/j.ymgme.2019.11.028

Aranda, Carolina, Mariana Gouveia-Pereira, Marina França, Marco Curiati, Dirceu Sole, Priya Kishnani, and Ana Maria Martins. “Infantile-onset Pompe disease and CRIM negative status: Immunomodulation with intravenous immunoglobulin as an alternative for regular immune tolerance induction.” In Molecular Genetics and Metabolism, 129:S22–S22. Elsevier BV, 2020. https://doi.org/10.1016/j.ymgme.2019.11.028.

Aranda C, Gouveia-Pereira M, França M, Curiati M, Sole D, Kishnani P, et al. Infantile-onset Pompe disease and CRIM negative status: Immunomodulation with intravenous immunoglobulin as an alternative for regular immune tolerance induction. In: Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S22–S22.

Aranda, Carolina, et al. “Infantile-onset Pompe disease and CRIM negative status: Immunomodulation with intravenous immunoglobulin as an alternative for regular immune tolerance induction.” Molecular Genetics and Metabolism, vol. 129, no. 2, Elsevier BV, 2020, pp. S22–S22. Crossref, doi:10.1016/j.ymgme.2019.11.028.

Aranda C, Gouveia-Pereira M, França M, Curiati M, Sole D, Kishnani P, Martins AM. Infantile-onset Pompe disease and CRIM negative status: Immunomodulation with intravenous immunoglobulin as an alternative for regular immune tolerance induction. Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S22–S22.